Compare APOG & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | EVMN |
|---|---|---|
| Founded | 1949 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.1M | 717.5M |
| IPO Year | 1994 | N/A |
| Metric | APOG | EVMN |
|---|---|---|
| Price | $40.03 | $20.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $47.00 | $43.88 |
| AVG Volume (30 Days) | 188.2K | ★ 400.1K |
| Earning Date | 04-24-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $1,404,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.07 | N/A |
| P/E Ratio | $15.92 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $30.75 | $13.89 |
| 52 Week High | $46.14 | $33.20 |
| Indicator | APOG | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 43.92 |
| Support Level | $36.90 | $18.64 |
| Resistance Level | $40.14 | $21.21 |
| Average True Range (ATR) | 1.31 | 1.38 |
| MACD | 0.21 | 0.05 |
| Stochastic Oscillator | 69.79 | 27.99 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.